P2X2 Receptor Antagonist
-
Minodronic acid
0 ImagesSynonyms: YM-529Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer.
-
NF279
0 ImagesNF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection.
-
RO-3
0 ImagesCat. No.: HY-19978CAS No.: 1026582-88-6RO-3 is a potent, and orally active P2X3 and P2X2/3 antagonist with pIC50s of 5.9 and 7.0 for human homomultimeric P2X3 and heteromultimeric P2X2/3 receptors, respectively. RO-3 shows selectivity for P2X3 and P2X2/3 over all other functional homomultimeric P2X receptors (IC50 >10 μM at P2X1,2,4,5,7).
-
Minodronic acid-d4
0 ImagesCat. No.: HY-16322SCAS No.: 1807367-80-1Synonyms: YM-529-d4Minodronic acid-d4 (YM-529-d4) is deuterium labeled Minodronic acid (HY-16322). Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer.
-
TNP-GTP tetrasodium
0 ImagesCat. No.: HY-137609ASynonyms: TNP-Guanosine 5'-triphosphate tetrasodiumTNP-GTP tetrasodium is a fluorescently labeled GTP (HY-113225) derivative. TNP-GTP tetrasodium can inhibit glutamate dehydrogenase (Ki = 2.7 μM). TNP-GTP tetrasodium is an antagonist of the purinergic P2X2 and P2X2/3 receptors with IC50 values of 0.4 and 1.2 nM, respectively. TNP-GTP tetrasodium also inhibit rat soluble guanylyl cyclase (Ki = 11 nM).
-
PPADS
0 ImagesCat. No.: HY-108960CAS No.: 149017-66-3PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain.
-
P2X2R antagonist-1
0 ImagesCat. No.: HY-184044CAS No.: 13112-05-5P2X2R antagonist-1 (compound 66) is a P2X2 receptor antagonist derived from Reactive Blue 4 (HY-125815). P2X2R antagonist-1 shows high selectivity for P2X4, P2X7, P2Y2, P2Y4, P2Y6 and P2Y12 receptors, moderate selectivity for P2X1 and P2X3 receptors, and exhibits higher potency toward homomeric P2X2 receptors than heteromeric P2X2/3 receptors. P2X2R antagonist-1 competitively inhibits ATP-mediated currents. P2X2R antagonist-1 can be used in research related to pain and urinary incontinence.
-
P2X3 antagonist 40
0 ImagesCat. No.: HY-183056P2X3 antagonist 40 is a P2X3 antagonist with a human P2X3 receptor pIC50 < 4.52. P2X3 antagonist 40 can be used for research on ATP-mediated proinflammatory fingerprint, including overactive bladder, pain, and chronic cough.
